- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 4,50 € / 4,58 € |
| Spread | +1,78% |
| Schluss Vortag | 4,52 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief - Tageshoch - | |
| 52W-Tief - 52W-Hoch 6,00 € | |
| Jahrestief - Jahreshoch 5,45 € | |
| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | -103,20 $ |
| Jahresüberschuss in Mio. | -95,88 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -0,48 $ |
| Gewinnrendite | -55,92% |
| Umsatzrendite | - |
| Return on Investment | -45,04% |
| Marktkapitalisierung in Mio. | 608,45 $ |
| KGV (Kurs/Gewinn) | -6,40 |
| KBV (Kurs/Buchwert) | 3,53 |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +80,54% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 4,46 € | -1,33% | 4,52 € | 12:30 | |
| Frankfurt | 4,48 € | +1,36% | 4,42 € | 08:23 | |
| München | 4,66 € | -2,51% | 4,78 € | 13.03.26 | |
| Stuttgart | 4,54 € | +0,89% | 4,50 € | 15:02 | |
| L&S RT | 4,54 € | -1,30% | 4,60 € | 15:53 | |
| NYSE | 5,18 $ | -1,05% | 5,235 $ | 15:30 | |
| Nasdaq | 5,18 $ | -1,24% | 5,245 $ | 15:30 | |
| AMEX | 5,21 $ | -3,70% | 5,41 $ | 13.03.26 | |
| Tradegate | 4,92 € | +8,85% | 4,52 € | 10.03.26 | |
| Quotrix | 4,54 € | -2,58% | 4,66 € | 07:27 | |
| Gettex | 4,58 € | 0 % | 4,58 € | 15:43 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 13.03.26 | 4,52 | 0 |
| 12.03.26 | 4,64 | 0 |
| 11.03.26 | 4,78 | 0 |
| 10.03.26 | 4,84 | 123 |
| 09.03.26 | 4,68 | 470 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 4,54 € | +8,37% |
| 1 Monat | 4,72 € | +4,24% |
| 6 Monate | 3,02 € | +62,91% |
| 1 Jahr | 2,54 € | +93,70% |
| 5 Jahre | 1,31 € | +275,57% |
| Marktkapitalisierung | 1,11 Mrd. € |
| Aktienanzahl | 203,47 Mio. |
| Streubesitz | 11,72% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,16% | NEA Management Company, LLC |
| +10,18% | Bain Capital Life Sciences Investors, LLC |
| +7,15% | TCG Crossover Management, LLC |
| +6,37% | Vestal Point Capital LP |
| +5,66% | BlackRock Inc |
| +5,14% | VR Adviser, LLC |
| +4,89% | Vanguard Group Inc |
| +4,82% | Nantahala Capital Management, LLC |
| +4,61% | Deerfield Management Co |
| +3,95% | Farallon Capital Management, L.L.C. |
| +2,08% | ADAR1 Capital Management LLC |
| +2,04% | Emerald Advisers, LLC |
| +1,94% | Wellington Management Company LLP |
| +1,72% | Geode Capital Management, LLC |
| +1,54% | Rosalind Advisors, Inc. |
| +1,42% | Sofinnova Ventures |
| +1,42% | State Street Corp |
| +1,26% | Emerald Mutual Fund Advisers Trust |
| +0,76% | Sphera Funds Management Ltd. |
| +0,65% | SUPERSTRING CAPITAL MANAGEMENT LP |
| +6,51% | Weitere |
| +11,72% | Streubesitz |
Zahlen für Q1/24
- Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024
- the Company Continues to Believe it is Sufficiently Capitalized into 2026
https://savarapharma.com/investors/press-releases/release/?id=14706
